Asia Pacific Leukemia Therapeutics market has been estimated at USD 1.63 Billion in 2022 and is projected to reach USD 2.78 Billion by 2027, at a CAGR of 11.2% during the forecast period from 2022 to 2027.
Leukemia is the cancer of the white blood cells or the bone marrow, which occurs due to an abnormal increase in the count of white blood cells. There are several types of leukemia that appear suddenly and progress rapidly over days to weeks. It can be identified by the spread of the diseases and by the type of the blood cell that is affected.
The market for Leukemia Therapeutics in Asia-Pacific region is mainly driven due to factors like increasing aging population due to which there is an increasing occurrence of leukemia, along with increasing awareness of patients regarding most recent technological developments.
But, the market growth is feared to drop due to the high costs of drugs and therapies.
This research report on the APAC Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories
By Disease Condition:
By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.
The Asia-pacific market is growing at a very high rate, due to the rising consumer market, favorable government support for enhanced healthcare infrastructure, and raising awareness for healthcare among the population in developing nations of the region.
The Top companies leading in the APAC Leukemia Therapeutics market profiled in this report are Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]